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BACKGROUND Bioresorbable everolimus-eluting scaffolds (BVS) and
metallic drug-eluting stents with bioabsorbable polymers (MBP-DES)
have shown positive clinical results in studies. Direct comparative
evaluation between both for the process of endothelialization is
lacking and could be relevant to deﬁne their safety proﬁle and sub-
sequently estimate the appropriate duration of dual antiplatelet-
therapy. In this study we sought to evaluate endothelialization of BVS
and MBP-DES, implanted both in same patient, with OCT performed at
6 and 12 months.
METHODS Multicenter (16 centers) prospective study. Patients were
recruited when requiring stent implantation (without overlapping) in
at least two separate lesions of similar morphologic characteristics.
Each lesion was randomized to be treated with a BVS or a MBP-DES
(Synergy TM, Orsiro TM or Biomatrix TM). After the procedure pa-
tients were scheduled alternatively for 6 or 12 months evaluation with
optical coherence tomography. Co-primary endpoints are % of un-
covered struts at 6 and 12 months.
RESULTS Up to date 100 patients have been included all treated in at
least one lesion with a BVS and in at least other lesion with a MBP-DES
(50% Synergy TM, 25% Orsiro TM and 25% Biomatrix TM). Among
these, 20 patients have been so far examined with OCT at 6 months.
The proportion of uncovered struts was 2.8  2.4 % with MBP-DES and
3.2  3.8 % with BVS (p¼0.4) and the proportion of malapposed struts
was 2.2  2.8 % and 2  3.7% respectively (p¼0.7). Maximal malap-
position area was 1  1.3 mm2 with MBP-DES and 1.8  2.4 mm2 with
BVS (p¼0.1). Evaginations or protusion of covered struts were more
common with BVS.
CONCLUSIONS Pending of ﬁnal follow up and analysis of the whole
cohort, at 6 months the proportion of uncovered struts is very low
and comparable between bioresorbable everolimus-eluting scaffolds
and metallic drug-eluting stents with bioabsorbable polymers. Dif-
ferences in evagination and malapposition magnitude could be
observed.
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BACKGROUND Even though the limited randomized data suggest
similar angiographic and intermediate-term clinical outcomes in pa-
tients treated with bioresorbable scaffolds (BRS) and those treated
with new generation everolimus eluting stents (EES), real world
studies have revealed some worrying signals of increased rates of
stent thrombosis (ST) in patients treated with BRS. Several potential
ST mechanisms have been proposed, one of which involves over-
lapping segments. This propensity matched study sought to evaluate
procedural and clinical outcomes amongst stable angina patients
treated with percutaneous coronary intervention (PCI) with over-
lapping BRS or new generation EES.
METHODS A total of 109 consecutive stable angina patients treated
with overlapping BRS (May 2012-July 2014) and 149 patients treated
with overlapping new generation EES (January 2011 and July 2014) in
2 Italian centers were included. Exclusion criteria included bifurcation
lesions treated with a 2-stents/scaffolds strategy and patients with
end stage renal failure. After propensity matching, a total of 70 stable
angina patients treated with overlapping BRS and 70 patients treated
with overlapping new generation EES were included. The primary
outcomes were angiographic and procedural success. Secondary
endpoints included 1-year rate of major adverse cardiovascular events
(MACE: deﬁned as the composite of all-cause mortality, non-proce-
dural myocardial infarction (MI) and target-vessel revascularization).
RESULTS Post procedural acute gain was signiﬁcantly lower in pa-
tients treated with BRS (1.820.66mm versus 2.030.68mm,
p¼0.033). Angiographic success (BRS vs. EES: 94.3% vs. 95.5%,
p¼0.742), rates of periprocedural MI (BRS vs. EES: 7.1% vs. 5.7%,
p¼0.730) and procedural success (BRS vs. EES: 88.6% vs. 89.9%,
p¼0.854) were similar between the two groups. At 1-year follow up,
the estimated MACE rate was not signiﬁcantly different between the
two groups (BRS vs. EES: 14.5% vs. 15.9%; Plog-rank¼0.427). Similarly,
no signiﬁcant differences were seen in 1-year rates of TVR (BRS vs.
EES: 11.7% vs. 8.1%, Plog-rank¼0.8), TLR (BRS vs. EES: 7.5% vs. 6.5%,
Plog-rank¼0.917) or follow-up MI (BRS vs. EES: 0% vs. 0%,
Plog-rank¼0.098). No cases of deﬁnite stent thrombosis were observed
in the two groups.
CONCLUSIONS This small propensity matched study demonstrated
that treating long lesions with overlapping scaffolds is feasible and
safe with acceptable procedural outcomes. Even though there was a
signiﬁcantly lower acute gain in the BRS group compared to EES, this
did not translate into worse clinical outcomes. Future, large ran-
domized trials are needed to assess the clinical performance of BRS
compared to new generation EES in patients implanted with over-
lapping scaffolds.
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BACKGROUND The bioresorbable vascular scaffold (BVS) may facili-
tate restoration of normal coronary physiology after resorption of the
scaffold. Conversely, early after BVS implantation the mean luminal
area is decreased in comparison with conventional metal stents.
Therefore, a randomized clinical trial of BVS vs. metal drug eluting
stent (DES) was initiated, utilizing positron emission tomography
(PET) perfusion imaging to assess the impact of these phenomena on
(hyperemic) myocardial blood ﬂow (MBF) and CFR over a three year
period (VANISH-trial). These are the one-month results of the ongoing
